2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. 17β-HSD

17β-HSD

17beta-HSD; 17β-hydroxysteroid dehydrogenases; 17 beta-hydroxysteroid dehydrogenase

 

17β-HSD Isoform Specific Products:

17β-HSD Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148814
    BI-3231
    		Inhibitor 99.83%
    BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases.
    BI-3231
  • HY-138557
    AKR1C3-IN-4
    		Inhibitor 99.77%
    AKR1C3-IN-4 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research.
    AKR1C3-IN-4
  • HY-156735
    HSD17B13-IN-2
    		Inhibitor 99.72%
    HSD17B13-IN-2 (compound 1) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor. HSD17B13-IN-2 has cell experimental activity.
    HSD17B13-IN-2
  • HY-156736
    HSD17B13-IN-3
    		Inhibitor 99.78%
    HSD17B13-IN-3 (compound 2) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor. HSD17B13-IN-3 does not have cell experimental activity.
    HSD17B13-IN-3
  • HY-161227
    HSD17B13-IN-43
    		Inhibitor 99.68%
    HSD17B13-IN-43 (11) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-43
  • HY-159525
    Linustedastatum
    		Inhibitor
    Linustedastatum (Linustedastat) is a hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1) inhibitor.
    Linustedastatum
  • HY-164138
    17β-HSD5 inhibitor 3
    		Inhibitor
    17β-HSD5 inhibitor 3 (Compound 31) is an orally active inhibitor for 17β-HSD5 with an IC50 of 69 nM.
    17β-HSD5 inhibitor 3
  • HY-161979
    HSD17B13-IN-103
    		Inhibitor
    HSD17B13-IN-103 (Compound 44) is a HSD17B13 inhibitor. HSD17B13-IN-103 can be used in the study of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
    HSD17B13-IN-103
  • HY-161212
    HSD17B13-IN-8
    		Inhibitor 99.97%
    HSD17B13-IN-8 (1) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with IC50 values of <0.1 μM for Estradiol and <1 μM for LTB3. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-8
  • HY-128145
    HSD17B13-IN-41
    		Inhibitor
    HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH.
    HSD17B13-IN-41
  • HY-163243
    HSD17B13-IN-29
    		Inhibitor
    HSD17B13-IN-29 (Compound 53) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-29 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-29
  • HY-163249
    HSD17B13-IN-49
    		Inhibitor
    HSD17B13-IN-49 (Compound 81) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-49 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-49
  • HY-161229
    HSD17B13-IN-69
    		Inhibitor
    HSD17B13-IN-69 (Compound 11) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-69 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-69
  • HY-157627
    HSD17B13-IN-9
    		Inhibitor
    HSD17B13-IN-9 (252) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of 0.01 μM for 50 nM HSD17B13. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-9
  • HY-157708
    HSD17B13-IN-67
    		Inhibitor
    HSD17B13-IN-67 (Compound 677) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-67 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-67
  • HY-157722
    HSD17B13-IN-73
    		Inhibitor
    HSD17B13-IN-73 (Compound 85) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-73 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-73
  • HY-157717
    HSD17B13-IN-70
    		Inhibitor
    HSD17B13-IN-70 (Compound 39) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-70 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-70
  • HY-162223
    HSD17B13-IN-97
    		Inhibitor
    HSD17B13-IN-97 (compound 4) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor with an IC50 value of ≤0.1 µM. HSD17B13-IN-97 has the potential for the research of Nonalcoholic fatty liver diseases (NAFLDs), nonalcoholic steatohepatitis (NASH) or or drug induced liver injury (DILI).
    HSD17B13-IN-97
  • HY-161216
    HSD17B13-IN-15
    		Inhibitor
    HSD17B13-IN-15 (Compound 6) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-15 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI).
    HSD17B13-IN-15
  • HY-162219
    HSD17B13-IN-93
    		Inhibitor
    HSD17B13-IN-93 (Compound 9) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol that is greater than 0.1 μM and less than or equal to 0.5 μM. HSD17B13-IN-93 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-93
17β-HSD Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.